A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

Clinical trial NCT04713553 · COMPLETED

Trial details

NCT number: NCT04713553
Sponsor: BioNTech SE
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

SARS-CoV-2 Infection COVID-19

Start date: 2021-02-15
Primary completion: 2021-07-22
Enrollment: 1574

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.